Rapport Therapeutics reported its business update for the fourth quarter and full year ended December 31, 2024. The company confirmed that its RAP-219 Phase 2a trial in patients with refractory focal epilepsy continues to advance, with patient enrollment and dosing progressing as planned. Topline results for this pivotal trial remain on track for the third quarter of 2025.
The company also reiterated confidence in RAP-219's differentiated precision profile, citing recently released PET and MAD-2 trial results that demonstrated neuroanatomical specificity and favorable tolerability. These Phase 1 data were derived from 100 healthy subjects, reinforcing the drug's potential as a transformative medicine.
Looking ahead, Rapport anticipates initiating a Phase 2a trial for RAP-219 in bipolar mania during the third quarter of 2025. Planning for a Phase 2a trial in diabetic peripheral neuropathic pain is also ongoing, despite a previous clinical hold on the IND application for this indication. The company expects its cash runway to extend through the end of 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.